Key points from article :
After a $90 million Series C funding round, BioAge has moved quickly to start the new year.
BioAge utilizes broad anti-aging pathways to target specific age-related diseases.
Uses an invaluable dataset, an AI-driven approach, and therapeutics with previously established safety profiles.
In March, BioAge launched a phase 2a trial for unexplained anemia of aging.
Announced another phase 2 trial for COVID-19 in patients over 60 years old.
Plans to start its first clinical trial with BGE-105 in the first quarter of next year.
BGE-105 is an APJ agonist, a peptide that decreases with age in both rodents and humans.
The drug’s first indication will be specifically for sarcopenia or recovery from extended bed rest.
“A major milestone toward our vision... separate growing older from disability and disease, dramatically improving the quality of life as we age,” - Kristen Fortney, CEO of BioAge.
Ongoing trials in aging and newly licensed drug for muscle aging position it as a top longevity company.
